On August 27, 2025, the Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), will host a hybrid public meeting on "Demand Forecasting for Controlled Substances.” This meeting will include exploration of the complex factors that are considered when estimating the medical, scientific, and reserve stock needs for Schedule I and Schedule II substances, such as opioids and stimulants.

The Food and Drug Administration (FDA) and the Reagan-Udall Foundation are pleased to host the sixth Online Controlled Substances Summit.

Each year, the Reagan-Udall Foundation for the FDA's Board of Directors conducts an annual public meeting to highlight our activities in support of the U.S. Food and Drug Administration.

The Reagan-Udall Foundation for the FDA, in cooperation with the Food and Drug Administration, hosted a Food Traceability Rule public webinar featuring experts from various sectors of the food industry and FDA.

The Reagan-Udall Foundation for the FDA, in cooperation with the Food and Drug Administration, convened a hybrid public meeting to gather input on the clinical use and safety concerns associated with orally ingestible unapproved prescription drug products containing fluoride for use in children.

Celebrating outstanding achievement in regulatory science

The Reagan-Udall Foundation for the FDA, in collaboration with the Food and Drug Administration (FDA), hosted a virtual, public workshop to explore opportunities to optimize therapeutic development to address primary mitochondrial diseases.

Explore FDA draft guidance in this Real-World Evidence Webinar hosted by the Reagan-Udall Foundation and FDA on Nov. 22, 2024—focusing on integrating randomized controlled trials into routine clinical practice for drugs and biologics.